2-(4-Methoxy-phenyl)-6,7-dimethyl-chromen-4-one | 80972-97-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(4-Methoxy-phenyl)-6,7-dimethyl-chromen-4-one
• 英文别名: 2-(4-Methoxyphenyl)-6,7-dimethyl-4H-1-benzopyran-4-one；2-(4-methoxyphenyl)-6,7-dimethylchromen-4-one
• CAS: 80972-97-0
• 化学式: C₁₈H₁₆O₃
• 分子量: 280.323
• InChiKey: AIHAGXATMUIUKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-Methoxy-phenyl)-6,7-dimethyl-chromen-4-one 、 盐酸胍 、 氢氧化钾 、 水 、 甲醇 生成 2-[2-Amino-6-(4-methoxy-phenyl)-pyrimidin-4-yl]-4,5-dimethyl-phenol
  参考文献：
  名称：

  THAKAR, K. A.;GILL, C. H., J. INDIAN CHEM. SOC., 1983, 60, N 7, 671-673

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(2-Hydroxy-4,5-dimethyl-phenyl)-3-(4-methoxy-phenyl)-propane-1,3-dione 在 盐酸 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以90%的产率得到2-(4-Methoxy-phenyl)-6,7-dimethyl-chromen-4-one
  参考文献：
  名称：

  Thakar, K. A.; Gill, C. H., Journal of the Indian Chemical Society, 1983, vol. 60, p. 668 - 670

  摘要：

  DOI：

文献信息

• Cytidine deaminase expression level in cancer as a new therapeutic target
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US11209421B2

  公开（公告）日：2021-12-28

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.

  本发明提供了一种选择肿瘤患者接受抗肿瘤化合物治疗的体外方法，其中该方法包括测量所述患者的癌症样本中CDA（胞苷脱氨酶）的表达水平的步骤。当癌症样本的CDA表达水平低于参考表达水平时，表明患者适合使用选自表4化合物组成的组的抗肿瘤化合物，特别是氨基黄酮进行治疗。或者，当癌症样本的CDA表达水平高于参考表达水平时，表明患者适合使用选自表3化合物组成的组的抗肿瘤化合物，特别是达沙替尼进行治疗。
• THAKAR, K. A.;GILL, C. H., J. INDIAN CHEM. SOC., 1983, 60, N 7, 668-670
  作者：THAKAR, K. A.、GILL, C. H.

  DOI：——

  日期：——
• CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20190293629A1

  公开（公告）日：2019-09-26

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.
• Thakar, K. A.; Gill, C. H., Journal of the Indian Chemical Society, 1983, vol. 60, p. 668 - 670
  作者：Thakar, K. A.、Gill, C. H.

  DOI：——

  日期：——
• THAKAR, K. A.;GILL, C. H., J. INDIAN CHEM. SOC., 1983, 60, N 7, 671-673
  作者：THAKAR, K. A.、GILL, C. H.

  DOI：——

  日期：——